Final Reminder: (Nasdaq: NMRD) Is A Low Float Breakout Idea Backed By 5 Key Potential Catalysts
In the realm of healthcare and wellness, tracking a company determined to disrupt markets of such colossal magnitude is not just important; it's imperative.
The global Type 2 diabetes market, on the cusp of ballooning to a staggering almost $59Bn by 2025, presents both immense promise and profound challenges.
Keeping a vigilant eye on companies looking to make their presence known in this market is crucial, as their innovations could potentially reshape diabetes management, altering the lives of millions and redefining the economic landscape.
Moreover, the $50+Bn pre-diabetic market is equally significant.
Early intervention and prevention strategies in this space have the potential to avert the progression of diabetes, reducing both the human suffering and the financial burden on healthcare systems.
Simultaneously, the wearable health-tech sector, estimated to reach $60Bn by 2023, is poised to revolutionize weight loss and wellness applications.
In this era of unprecedented growth and innovation, one Nasdaq traded company's actions could start garnering Wall Street's attention in a big way.
And with a recent Zacks Equity Research "Upgrade," a low float of fewer than 13Mn shares, strong retention rates from a key metabolic health program, and SFDA approval that'll speed up commercialization efforts, this Nasdaq idea needs immediate attention.
Drop everything this second and pull up:
*Nemaura Medical Inc. (NMRD)*
Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The Company is currently also commercializing sugarBEAT® and proBEAT™.
And right now, NMRD has several potential catalysts to focus on ahead of Monday's opening bell. Check them out:
No. 1 - Interim Results From Miboko Program Holds Eye-Catching Retention Rates
No. 2 - NMRD's Low Float Suggests Volatile Potential
No. 3 - sugarBEAT® Receives SFDA Approval (Huge News For Commercialization Efforts)
No. 4 - Corporate Highlights Paint Nemaura To Be Hurtling Towards Bright Future
No. 5 - NMRD Hits The Gas On Pilot Expansion Of proBEAT™ (Huge Step Towards Revenue Generation)
But more on those in a second...
What Is The Market Space Nemaura Is Trying To Address?
A recent article in Forbes states:
- Over 11% of the US population is known to be diabetic; that translates into 37.3Mn people. Compounding the problem are approximately 8.5Mn people who have diabetes but remain undiagnosed.
- People with diagnosed diabetes incur average medical expenditures of $16,752 per year, of which about $9,601 is attributed to diabetes.
- The CDC estimates that 96Mn adults (38% of the population) in the United States are pre-diabetic and 80% of them do not know that they have it!
The Future Of Diagnostic Technology
BEAT® Technology Platform
Convenient, timely and painless, Nemaura's needle-free, patented BEAT® sensor is applied to the skin via a small unobtrusive patch and measures.
Transmitting this data to users and / or healthcare professionals via a Smartphone App, the technology will allow for medical conditions and chronic diseases to be monitored for better disease management or treatment.
Applications of Nemaura's technology include: glucose monitoring, temperature monitoring, lactate monitoring, alcohol monitoring, and substance abuse monitoring.
Miboko - Your Health, Your Way